Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity
Executive Summary
The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.
You may also be interested in...
EU Updates Definition Of ‘Similarity’ For Orphans In View Of Advances In Gene And Cell Therapies
Practical advice has also been issued on how the concept of similarity should be applied to advanced therapy medicinal products.
Pharma Welcomes Clarity On Similarity Assessment Of ATMPs Under EU Orphan Law
As the European Commission reviews the concept of similarity within the context of EU orphan drugs legislation, it has introduced a new section on advanced therapy medicinal products to clarify how similarity assessments should be carried out for such products. While the industry has welcomed this new guidance, it urges caution on this front as R&D in this field is still evolving.
New Guidance Brings Welcome Clarity on Practical Application of EU Orphan Drugs Law
EU pharmaceutical companies have welcomed new European Commission guidance that provides greater clarity on how several key provisions of the legislation on orphan drugs should be applied in practice.